foxo4 dri senolytic 2024 study Development of a novel by precise disruption of FOXO4-p53 complex The disordered p53 transactivation domain
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications FOXO4 DRI 10mg vial Description RCpeptides FOXO4 DRI: The Senolytic Peptide That Targets Zombie Cells and Aging Revolution Health & Wellness foxo4 dri senolytic peptide human trial 2024 FOXO4 DRI UK Senolytic Peptide Research Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv
Pay in 4 interest-free payments of $5.26 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10




